This study explores how breast tumors surviving chemotherapy appear to activate complex programs of immune modulation. The study population was divided into two arms; the first was signified with interferon response genes characterized by Cd274, with the second arm being a population with p53 signaling and CD80 expression. Study results failed to fully eliminate the tumors, even with combination strategies. The study underscored the importance of rational immune targeting strategies, particularly with the challenge of eliminating residual disease populated by senescent cells.
Reference: Shahbandi A, Chiu FY, Ungerleider NA, et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer. 2022;3(12):1513-1533. doi:10.1038/s43018-022-00466-y
